ECOG-ACRIN EAY131-Z1M

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

(See required screening study ECOG-ACRIN EAY131)

Accrual to EAY131-Z1M is suspended, effective September 27, 2022.

NCT#02465060